SecBot SecBot
8-K ·Filed Aug 3, 2026

KROS

Keros Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago SEC0001664710-26-000048
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

This is a routine quarterly update for a pre-revenue clinical-stage biotech. The key catalyst to watch is the Phase 2 rinvatercept DMD data expected in H1 2027. Cash runway into H1 2028 provides ample time to reach that milestone without near-term financing risk. No material surprise vs expectations, the stock is likely to trade on pipeline news, not this quarter's financials.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

KROS drug pipeline →

rinvatercept

● Neutral Named in this 8-K
Impact
Phase
Phase 2
Time to market
Unknown — the drug is in Phase 2 for DMD with initial data expected H1 2027. If successful, Phase 3 trials and regulatory filing would follow, putting potential approval several years away (likely 2029-2031 at the earliest).
Next catalyst
None dated

What to watchWatch for the Phase 2 DMD initial data readout for rinvatercept expected in H1 2027, and any regulatory engagement updates for the ALS program in H2 2026. The stock trades at ~$11.23 with analyst mean price target of ~$19.83 (69% upside), but the stock is 18.8% below its 200-day SMA, reflecting the pre-revenue, binary-risk profile typical of clinical-stage biotechs.

Price Chart

Loading chart...

Executive Summary

Keros Therapeutics reported Q2 2026 results with a net loss of $28.7M ($1.45/share), slightly narrower than the $30.7M loss in Q2 2025. The company initiated a Phase 2 trial for rinvatercept in Duchenne muscular dystrophy, with initial data expected in H1 2027. Cash runway extends into H1 2028, providing a long operational horizon for a clinical-stage biotech with no approved products.

Key Financial Metrics

EPS
−$1.45
est −$1.25 · -16.0%
Revenue
$0.00
Rating
in line

Key Facts

  • Net loss of $28.7M in Q2 2026 vs $30.7M loss in Q2 2025
  • EPS of -$1.45 vs -$0.76 in Q2 2025 (wider loss per share due to lower share count)
  • Revenue was $0 in Q2 2026 vs $18.2M in Q2 2025 (prior year included Takeda license revenue)
  • Cash and equivalents $257.6M as of June 30, 2026, down from $287.4M at Dec 31, 2025
  • Cash runway expected into first half of 2028
  • Phase 2 DMD trial for rinvatercept initiated; initial data expected H1 2027
  • R&D expenses fell to $22.3M from $43.5M due to elritercept transition to Takeda and restructuring

Financial Impact

Net loss of $28.7M; cash burn of ~$29.8M in H1 2026

revenuenet losscasheps

Risk Factors

  • No approved products or revenue stream
  • Clinical trial failure risk for rinvatercept and elritercept
  • Cash burn of ~$30M per half-year; eventual need for additional financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
64% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001664710-26-000048
Document: kros-20260803.htm0001664710-26-000048
Document: 0001664710-26-000048-index-headers.html0001664710-26-000048
Document: 0001664710-26-000048-index.html0001664710-26-000048
Document: 0001664710-26-000048.txt0001664710-26-000048
8-K Data (Synthetic)0001664710-26-000048

Track record

27 reports on KROS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 3, 2026